Blog Archive

You are viewing the monthly archive for: August, 2014

What to Expect When Expecting… a Biotech Acquisition

What to Expect When Expecting… a Biotech Acquisition We’ve all either been there in person or heard the stories. Acquisitions and mergers are all over and through the last 15 years in the industry, our office has seen our fair share. Just in Massachusetts alone, we saw Takeda and Millennium, Genzyme and Sanofi, Sepracor and DSP, MGI and Eisai, and more recently, the…

Read more »

Prestige Scientific Recently Completes Three Searches

Prestige Scientific Recently Completes Three Searches BOSTON, MA- August 28, 2014 – Prestige Scientific, an executive search firm that advises clients on recruiting impactful leaders with proven abilities to increase productivity, decrease expenses, and mitigate business risk in the drug development process, today announced its successfully completed searches for two Global Directors of Regulatory Affairs and a Head of Purchasing/Procurement.…

Read more »

4 Things to Know About Highest VC Funded Biotech Cities in Q2 14

4 Things to Know About Highest VC Funded Biotech Cities in Q2 14 1. These are the Top 5 I. San Francisco $866M II. Boston $540M III. San Diego $167M IV. NY $125M V. Great Lakes $123M 2. $1.8B on 122 deals 3. The best Q2 since 1995 4. Cause for VC investments? Numerous IPO’s in the last 18 months…

Read more »

5 Things to Know About Baxter’s Move to Cambridge

1. Baxter HQ’s are in Deerfield, IL 2. They are in early stages of dividing the company into biopharma and medical product units 3. They’re looking for 150-200k sq/ft in East Cambridge initially and another 200K sq/ft at a later date 4. Their move should be finalized by mid-2015 5. Baxter has 100 person a plant in Milford, MA by acquiring late…

Read more »

Top 6 Reasons Pharma Execs Are Losing Sleep

A new survey of Big Pharma CEO’s shows that the concerns that once kept them up at night have shifted. For instance, top execs are less likely these days to worry about recruiting talent, setting up an effective organizational chart, and getting the most out of their R&D spending. Regulatory compliance? Less scary than before. Same goes for social responsibility.…

Read more »